Experienced in Richter Syndrome

Dr. Steven H. Applebaum

Hematology Oncology | Hematology | Oncology
The Regents Of The University Of California
2020 Santa Monica Blvd, Suite 210, 
Santa Monica, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Richter Syndrome
The Regents Of The University Of California
2020 Santa Monica Blvd, Suite 210, 
Santa Monica, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Steven Applebaum is a Hematologist Oncology specialist and a Hematologist in Santa Monica, California. Dr. Applebaum is rated as an Experienced provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Breast Cancer in Men, and Anemia.

His clinical research consists of participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Ronald Reagan UCLA Medical Center
Huntington Hospital
USC Verdugo Hills Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
2020 Santa Monica Blvd, Suite 210, Santa Monica, CA 90404
Other Locations
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
625 S Fair Oaks Ave, Suite 320, Pasadena, CA 91105

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
Enrollment Status: Recruiting
Publish Date: January 13, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
View 1 Less Clinical Trial
Similar Doctors
Distinguished in Richter Syndrome
Dr. Greg R. Angstreich
Hematology Oncology | Hematology | Oncology
Distinguished in Richter Syndrome
Dr. Greg R. Angstreich
Hematology Oncology | Hematology | Oncology

USC Care Medical Group Inc

1520 San Pablo St, Fl 4, 
Los Angeles, CA 
 (16.0 miles away)
800-872-2273
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Greg Angstreich is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. Angstreich is rated as a Distinguished provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Richter Syndrome, Chronic Lymphocytic Leukemia (CLL), B-Cell Lymphoma, and Chronic B-Cell Leukemia (CBCL).

Gary J. Schiller
Distinguished in Richter Syndrome
Dr. Gary J. Schiller
Hematology Oncology | Hematology | Oncology
Distinguished in Richter Syndrome
Dr. Gary J. Schiller
Hematology Oncology | Hematology | Oncology

The Regents Of The University Of California

200 Medical Plz, 
Los Angeles, CA 
 (3.1 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gary Schiller is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. Schiller is rated as an Elite provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Distinguished in Richter Syndrome
Dr. David M. Hoffman
Hematology Oncology | Hematology | Oncology
Distinguished in Richter Syndrome
Dr. David M. Hoffman
Hematology Oncology | Hematology | Oncology

Cedars-Sinai Medical Care Foundation

8723 Alden Dr, Suite 260, 
Los Angeles, CA 
 (6.4 miles away)
310-248-8299
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Hoffman is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. Hoffman is rated as a Distinguished provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Iron Deficiency Anemia, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Myelodysplastic Syndrome (MDS).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Applebaum's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 43 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile